Glaxosmithkline Consumer Nigeria Plc which is engaged in the manufacturing, marketing and distribution of a wide range of healthcare brands has released its annual report and consolidated and separate financial statements for the year ended 31 December 2021 with 5.88% rise in group profit for the year to N658.811 million from N622.230 million in 2020.

Group revenue for the year also rose to N22.450 billion from N21.295 billion in 2020.

Menawhile, the board has recommended to members a dividend of N0.45k to be paid for the year to shareholders, representing 45k per ordinary share to be payable on 27 May 2022. The group’s products include the Consumer Healthcare brands such as Panadol, Sensodyne, Andrews Liver Salt and Macleans and a range of internationally acclaimed pharmaceuticals, including Augmentin, Ampiclox and Amoxil (antibiotics); Zentel (the anthelmintic), and vaccines.